Scribd Logo
Upload

Welcome to Scribd!

  • 305 views

    Apixaban 5 PDF

    Uploaded by

    Wanie Al-basri
    This document summarizes the drug Apixaban (Eliquis). It is an oral anticoagulant used to prevent stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. The standard dose is 5mg taken orally twice daily, though a reduced dose of 2.5mg twice daily is recommended for patients who are elderly, small, or have reduced kidney function. Notable adverse effects include bleeding risks and thromboembolic events. The drug has contraindications for patients with active pathological bleeding or hepatic disease. Monitoring includes routine blood tests and checking for signs of bleeding.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Apixaban 5 PDF

    Uploaded by

    Wanie Al-basri
    305 views2 pages
    This document summarizes the drug Apixaban (Eliquis). It is an oral anticoagulant used to prevent stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. The standard dose is 5mg taken orally twice daily, though a reduced dose of 2.5mg twice daily is recommended for patients who are elderly, small, or have reduced kidney function. Notable adverse effects include bleeding risks and thromboembolic events. The drug has contraindications for patients with active pathological bleeding or hepatic disease. Monitoring includes routine blood tests and checking for signs of bleeding.

    Original Title

    apixaban 5.pdf

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    This document summarizes the drug Apixaban (Eliquis). It is an oral anticoagulant used to prevent stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. The standard dose is 5mg taken orally twice daily, though a reduced dose of 2.5mg twice daily is recommended for patients who are elderly, small, or have reduced kidney function. Notable adverse effects include bleeding risks and thromboembolic events. The drug has contraindications for patients with active pathological bleeding or hepatic disease. Monitoring includes routine blood tests and checking for signs of bleeding.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    305 views2 pages

    Apixaban 5 PDF

    Uploaded by

    Wanie Al-basri
    This document summarizes the drug Apixaban (Eliquis). It is an oral anticoagulant used to prevent stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. The standard dose is 5mg taken orally twice daily, though a reduced dose of 2.5mg twice daily is recommended for patients who are elderly, small, or have reduced kidney function. Notable adverse effects include bleeding risks and thromboembolic events. The drug has contraindications for patients with active pathological bleeding or hepatic disease. Monitoring includes routine blood tests and checking for signs of bleeding.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    of 2

    A) Drug Description: H) Indication in FUKKM:

    5mg, pink, oval-shaped, bi- Prevention of stroke and systemic embo-


    convex, film coated tablets
    lism in adult patients with non-valvular
    atrial fibrillation (NVAF), with one or
    B) Class: more risk factors, such as prior stroke
    Anticoagulant (Factor Xa inhibitor) or transient ischaemic attack (TIA);
    Age ≥75 years; hypertension; diabetes
    mellitus; symptomatic heart failure
    C) Registration No. :
    (NYHA Class ≥ II). Restriction: only for
    MAL31085063ARZ renal patients.

    D) Price: I) Dose in FUKKM:


    RM 65.10/box i) 5mg taken orally BD.
    Ii) Dose reduction: 2.5mg taken orally
    E) Department: BD in NVAF patients with at least two of
    the following characteristics: age ≥ 80
    Cardiology
    years old, body weight ≤ 60kg, or serum
    creatinine ≥ 1.5mg/dL (133 µmole/L)
    F) Prescriber Category:
    A* (Consultant/Specialists for specific
    J) Administration:
    indication only)
    Oral Nasogastric Tube
    swallow whole tablets or may be crushed and
    G) Mechanism of action:
    5 mg and 2.5 mg may be suspended in 60 mL of
    Apixaban is a highly selective, orally bio- crushed and suspended water or D5W and
    available inhibits thrombin production, in water, 5% dextrose in promptly delivered
    conversion of fibrinogen to fibrin and through a nasogastric
    water (D5W), or apple tube Crushed ELIQUIS
    thrombus formation via selective and
    juice, or mixed with ap- tablets are stable in
    reversible inhibition of factor Xa (FXa), a
    plesauce and promptly water, D5W, apple
    part of the promthrombinase complex
    administered orally juice, and applesauce
    which catalyses the conversion of pro-
    thrombin to thrombin. for up to 4 hours.
    K) Adverse Drug Reactions:
    i) significant: Thromboembolic events (premature discontinuation), bleeding, spinal or epidural
    haematoma resulting to long term or permanent paralysis.
    Ii) Blood & lymphatic system disorders: anaemia, thrombocytopenia
    Iii) Gastrointestinal disorders: nausea, mouth or gingival haemorrhage, GI and rectal haemor-
    rhage
    iV) injury, poisoning and procedural complications : contusion
    V) Reproductive system and breast disorders: vaginal and urogenital haemorrhage
    Vi) vascular disorders: epistaxis, hematoma
    Vii) potentially fatal: serious bleeding

    L) Contraindications: N) Monitoring parameters:


    Active pathological bleeding, hepatic dis- CBC,aPTT, PT, SCr, LFT prior initiation or
    ease associated with coagulopathy & clini- clinically indicated, and atl least annualy
    cally relevant bleeding risks, conditions or thereafter. Signs & symptoms of bleeding or
    lesions with significant risk for major anemia.
    bleeding. Concomitant use with parenteral
    anticoagulants except when given to main-
    O) Storage:
    tain an open central venous or aterial cath-
    eter, or during catheter ablation, oral anti- Store at room temperate (20°C-25°C)
    coagulant except when switching to oral
    anticoagulant theraphy.
    P) References:
    M) Use in specific Population: Product leaflet, Micromedex, FUKKM, Mims-
    gateway, NPRA
    Lactation: not recommended
    Pregnancy: US FDA (B)
    Paediatric: not established
    Prepared by:
    Renal impairment: 2.5mg BD (refer I (ii))
    Nur Syazwanie bt Ahmad Hassan Basri
    Hepatic impairment: no adjustment in mild,
    not recommended in severe.

    You might also like